The effect of Lipoxin A

BMC Musculoskeletal Disorders

Volumn 10, Issue 1, 2009, Pages

  Li, Gang ^a   Wu, Ping ^b,c   Xu, Yao ^c   Yu, Yan ^c   Sun, Li ^c   Zhu, Liang ^c   Ye, Duyun ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; DEXTRANOMER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; LIPOXIN A; POLY(METHYL METHACRYLATE); PROSTAGLANDIN E2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BONE CEMENT; CYTOKINE; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ARTICLE; ASEPTIC LOOSENING; CALCIUM TRANSPORT; CALVARIA; CELL CULTURE; CELL LINE; COCULTURE; CONCENTRATION (PARAMETERS); CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OVARY INFLAMMATION; PROSTHESIS LOOSENING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOTAL HIP PROSTHESIS; WESTERN BLOTTING; ANIMAL; ARTHROPLASTY; CELL COMMUNICATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENETICS; INFLAMMATION; METABOLISM; METHODOLOGY; ORGAN CULTURE TECHNIQUE; OSTEITIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTHESES AND ORTHOSES; PROSTHESIS FAILURE; RNA INTERFERENCE; STANDARD; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY; BONE CEMENTS; CELL COMMUNICATION; CELL LINE; COCULTURE TECHNIQUES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; MACROPHAGES; MICE; ORGAN CULTURE TECHNIQUES; OSTEITIS; OSTEOBLASTS; POLYMETHYL METHACRYLATE; PROSTHESES AND IMPLANTS; PROSTHESIS FAILURE; RNA INTERFERENCE; UP-REGULATION;

EID: 67650711878     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-10-57     Document Type: Article

References (60)

1. [Evaluation of outcomes following total hip arthroplasty]. P Kokoszka P Staszczuk M Redman Z Pislewski K Pietrzak, Chir Narzadow Ruchu Ortop Pol 2008 73 2 94 100 18847001
2. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. W Ren DC Markel R Schwendener Y Ding B Wu PH Wooley, J Biomed Mater Res A 2008 85 4 1043 1051 17937417 (Pubitemid 351717973)
3. Why Revision Total Hip Arthroplasty Fails. BD Springer TK Fehring WL Griffin SM Odum JL Masonis, Clin Orthop Relat Res 2009 467 1 166 173 10.1007/s11999-008-0566-z 18975043
4. The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis. Z Shen TN Crotti KP McHugh K Matsuzaki EM Gravallese BE Bierbaum SR Goldring, Arthritis Res Ther 2006 8 3 R70 16613614 10.1186/ar1938
5. Antisense oligonucleotide targeting TNF-alpha can suppress Co-Cr-Mo particle-induced osteolysis. L Dong R Wang YA Zhu C Wang H Diao C Zhang J Zhao J Zhang, J Orthop Res 2008 26 8 1114 1120 10.1002/jor.20607 18327794
6. Are there biological markers of wear? TW Bauer AS Shanbhag, J Am Acad Orthop Surg 2008 16 Suppl 1 S68 71 18612017
7. Mechanisms of disease: Molecular insights into aseptic loosening of orthopedic implants. P Drees A Eckardt RE Gay S Gay LC Huber, Nat Clin Pract Rheumatol 2007 3 3 165 171 10.1038/ncprheum0428 17334339
8. Nonsurgical management of osteolysis: challenges and opportunities. CT Talmo AS Shanbhag HE Rubash, Clin Orthop Relat Res 2006 453 254 264 10.1097/01.blo.0000246531.59876.a8 17016218
9. Role of free radicals in aseptic loosening of hip arthroplasty. P Kinov A Leithner R Radl K Bodo GA Khoschsorur K Schauenstein R Windhager, J Orthop Res 2006 24 1 55 62 10.1002/jor.20013 16419969
10. Mediator interactions in macrophage/particulate bone resorption. SM Horowitz MA Purdon, J Biomed Mater Res 1995 29 4 477 484 10.1002/jbm.820290407 7622532
11. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. K Miyanishi MC Trindade T Ma SB Goodman DJ Schurman RL Smith, J Bone Miner Res 2003 18 9 1573 1583 10.1359/jbmr.2003.18.9.1573 12968666
12. Systemic trafficking of macrophages induced by bone cement particles in nude mice. PG Ren SW Lee S Biswal SB Goodman, Biomaterials 2008 29 36 4760 4765 10.1016/j.biomaterials.2008.09.004 18824259
13. Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cells. A Sabokbar Y Fujikawa S Neale DW Murray NA Athanasou, Ann Rheum Dis 1997 56 7 414 420 9486003 10.1136/ard.56.7.414 (Pubitemid 27345260)
14. The central role of wear debris in periprosthetic osteolysis. PE Purdue P Koulouvaris BJ Nestor TP Sculco, Hss J 2006 2 2 102 113 18751821 10.1007/s11420-006-9003-6
15. Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. HJ Heller JE Zerwekh FA Gottschalk CY Pak, Kidney Int 2007 71 8 808 815 10.1038/sj.ki.5002181 17311067
16. Osteoblasts and osteoclasts in bone remodeling and inflammation. Y Tanaka S Nakayamada Y Okada, Curr Drug Targets Inflamm Allergy 2005 4 3 325 328 10.2174/1568010054022015 16101541
17. The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. DP Pioletti A Kottelat, Biomaterials 2004 25 27 5803 5808 10.1016/j.biomaterials.2004.01.053 15172492
18. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. C Vermes R Chandrasekaran JJ Jacobs JO Galante KA Roebuck TT Glant, J Bone Joint Surg Am 2001 83-A 2 201 211 11216681 (Pubitemid 32163714)
19. Response of human osteoblasts to polymethylmetacrylate In vitro. G Zambonin S Colucci F Cantatore M Grano, Calcif Tissue Int 1998 62 4 362 365 10.1007/s002239900445 9504963
20. Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes. V Starosta K Pazdrak I Boldogh T Svider A Kurosky, J Immunol 2008 181 12 8688 8699 19050289
21. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. CN Serhan, Annu Rev Immunol 2007 25 101 137 10.1146/annurev.immunol.25.022106.141647 17090225
22. Lipoxins are potential endogenous antiinflammatory mediators in asthma. C Bonnans I Vachier C Chavis P Godard J Bousquet P Chanez, Am J Respir Crit Care Med 2002 165 11 1531 1535 10.1164/rccm.200201-053OC 12045128
23. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. AJ Merched K Ko KH Gotlinger CN Serhan L Chan, Faseb J 2008 22 10 3595 3606 10.1096/fj.08-112201 18559988
24. Effect of mangiferin on the development of periodontal disease: Involvement of lipoxin A(4), anti-chemotaxic action in leukocyte rolling. RR Carvalho CH Pellizzon L Justulin Jr SL Felisbino W Vilegas F Bruni M Lopes-Ferreira CA Hiruma-Lima, Chem Biol Interact 2009 179 23 344 50 10.1016/j.cbi.2008.10.041 19026997
25. [Cyclooxygenase 2 derived lipid mediators play a pivotal role in resolution of acute lung injury]. K Fukunaga, Nihon Kokyuki Gakkai Zasshi 2008 46 2 156 164 18318262
26. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases. S Yacoubian CN Serhan, Nat Clin Pract Rheumatol 2007 3 10 570 579 quiz 571 p following 589 10.1038/ncprheum0616 17906612
27. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6. FS Machado L Esper A Dias R Madan Y Gu D Hildeman CN Serhan CL Karp J Aliberti, J Exp Med 2008 205 5 1077 1086 18411340 10.1084/jem.20072416
28. Lipoxin biosynthesis in inflammatory bowel disease. MJ Mangino L Brounts B Harms C Heise, Prostaglandins Other Lipid Mediat 2006 79 12 84 92 10.1016/j.prostaglandins.2005.10.004 16516812
29. Signal transduction involved in protective effects of 15(R/S)-methyl-lipoxin A(4) on mesangioproliferative nephritis in rats. SH Wu XH Wu PY Liao L Dong, Prostaglandins Leukot Essent Fatty Acids 2007 76 3 173 180 10.1016/j.plefa.2006.12.006 17329090
30. Inflammatory response to implant particulates in a macrophage/osteoblast coculture model. SM Horowitz JB Gonzales, Calcif Tissue Int 1996 59 5 392 396 10.1007/s002239900145 8849407
31. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. H Yuan L Lanting ZG Xu SL Li P Swiderski S Putta M Jonnalagadda M Kato R Natarajan, Am J Physiol Renal Physiol 2008 295 2 F605 617 10.1152/ajprenal.90268.2008 18562637
32. -12/15-Lipoxygenase deficiency protects mice from allergic airways inflammation and increases secretory IgA levels. AR Hajek AR Lindley S Favoreto Jr R Carter RP Schleimer DA Kuperman, J Allergy Clin Immunol 2008 122 3 633 639 10.1016/j.jaci.2008.06.021 18692885
33. Dissecting asthma using focused transgenic modeling and functional genomics. DA Kuperman CC Lewis PG Woodruff MW Rodriguez YH Yang GM Dolganov JV Fahy DJ Erle, J Allergy Clin Immunol 2005 116 2 305 311 10.1016/j.jaci.2005.03. 024 16083784
34. NOX4 Mediates Hypoxia-Induced Proliferation of Human Pulmonary Artery Smooth Muscle Cells: The Role of Autocrine Production of TGF-beta1 and IGFBP-3. S Ismail A Sturrock P Wu B Cahill K Norman TP Huecksteadt KA Sanders TP Kennedy JR Hoidal, Am J Physiol Lung Cell Mol Physiol 2009 296 3 L489 99 10.1152/ajplung.90488.2008 19036873
35. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. A Regmi T Fuson X Yang J Kays C Moxham E Zartler S Chandrashekhar RJ Galvin, Bone 2005 36 2 284 291 10.1016/j.bone.2004.09.022 15780954
36. Modulation of the cross-talk between macrophages and osteoblasts by titanium-based particles. G Valles E Gil-Garay L Munuera N Vilaboa, Biomaterials 2008 29 15 2326 2335 10.1016/j.biomaterials.2008.02.011 18313744
37. Efficient Inhibition of wear debris-induced inflammation by locally delivered siRNA. X Peng K Tao T Cheng J Zhu X Zhang, Biochem Biophys Res Commun 2008 377 2 532 537 10.1016/j.bbrc.2008.10.026 18930023
38. Comparison of the roles of IL-1, IL-6, and TNFalpha in cell culture and murine models of aseptic loosening. N Taki JM Tatro R Lowe VM Goldberg EM Greenfield, Bone 2007 40 5 1276 1283 17236833 10.1016/j.bone.2006.12.053
39. Efficacy of etanercept for wear debris-induced osteolysis. LM Childs JJ Goater RJ O'Keefe EM Schwarz, J Bone Miner Res 2001 16 2 338 347 10.1359/jbmr.2001.16.2.338 11204434 (Pubitemid 32105415)
40. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. EM Schwarz AP Lu JJ Goater EB Benz G Kollias RN Rosier JE Puzas RJ O'Keefe, J Orthop Res 2000 18 3 472 480 10.1002/jor. 1100180321 10937636 (Pubitemid 30599625)
41. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. X Zhang SG Morham R Langenbach DA Young L Xing BF Boyce EJ Puzas RN Rosier RJ O'Keefe EM Schwarz, J Bone Miner Res 2001 16 4 660 670 10.1359/jbmr.2001.16.4.660 11315993 (Pubitemid 32230594)
42. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. PF Pollice RN Rosier RJ Looney JE Puzas EM Schwarz RJ O'Keefe, J Bone Joint Surg Am 2001 83-A 7 1057 1061 11451976 (Pubitemid 32662109)
43. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. EM Schwarz D Campbell S Totterman A Boyd RJ O'Keefe RJ Looney, J Orthop Res 2003 21 6 1049 1055 10.1016/S0736-0266(03)00093-7 14554218
44. Pro-inflammatory and anti-inflammatory circulating cytokines and periprosthetic osteolysis. S Fiorito L Magrini C Goalard, J Bone Joint Surg Br 2003 85 8 1202 1206 10.1302/0301-620X.85B8.12799 14653608
45. Bone-resorbing cytokines in serum of patients with aseptic loosening of hip prostheses. D Granchi E Verri G Ciapetti S Stea L Savarino A Sudanese M Mieti R Rotini D Dallari G Zinghi, J Bone Joint Surg Br 1998 80 5 912 917 10.1302/0301-620X.80B5.8513 9768909
46. Interleukin-6 in the blood of patients with total hip arthroplasty without loosening. P Hernigou L Intrator T Bahrami A Bensussan JP Farcet, Clin Orthop Relat Res 1999 366 147 154 10.1097/00003086-199909000-00018 10627728 (Pubitemid 29439348)
47. Interleukin-1 modulates periprosthetic tissue formation in an intramedullary model of particle-induced inflammation. NJ Epstein BA Warme J Spanogle T Ma B Bragg RL Smith SB Goodman, J Orthop Res 2005 23 3 501 510 10.1016/j.orthres.2004.10.004 15885468
48. Osteolytic properties of the synovial-like tissue from aseptically failed joint prostheses. MJ Perry FM Ponsford FY Mortuza ID Learmonth RM Atkins CJ Elson, Br J Rheumatol 1996 35 10 943 950 10.1093/rheumatology/35.10.943 8883431
49. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. CN Serhan, J Periodontol 2008 79 8 Suppl 1520 1526 10.1902/jop.2008.080231 18673006
50. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. CN Serhan N Chiang, Br J Pharmacol 2008 153 Suppl 1 S200 215 17965751 10.1038/sj.bjp.0707489
51. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. CN Serhan N Chiang TE Van Dyke, Nat Rev Immunol 2008 8 5 349 361 10.1038/nri2294 18437155
52. Lipid mediator class switching during acute inflammation: signals in resolution. BD Levy CB Clish B Schmidt K Gronert CN Serhan, Nat Immunol 2001 2 7 612 619 10.1038/89759 11429545
53. Inflammatory resolution: new opportunities for drug discovery. DW Gilroy T Lawrence M Perretti AG Rossi, Nat Rev Drug Discov 2004 3 5 401 416 10.1038/nrd1383 15136788 (Pubitemid 38618123)
54. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. T Lawrence M Bebien GY Liu V Nizet M Karin, Nature 2005 434 7037 1138 1143 10.1038/nature03491 15858576
55. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? CN Serhan, Prostaglandins 1997 53 2 107 137 10.1016/S0090-6980(97)00001-4 9112289
56. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. M Chen M Divangahi H Gan DS Shin S Hong DM Lee CN Serhan SM Behar HG Remold, J Exp Med 2008 205 12 2791 2801 18955568 10.1084/jem.20080767
57. Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism. BD Levy NW Lukacs AA Berlin B Schmidt WJ Guilford CN Serhan JF Parkinson, Faseb J 2007 21 14 3877 3884 10.1096/fj.07-8653com 17625069
58. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. CN Serhan JF Maddox NA Petasis I Akritopoulou-Zanze A Papayianni HR Brady SP Colgan JL Madara, Biochemistry 1995 34 44 14609 14615 10.1021/bi00044a041 7578068 (Pubitemid 3000720)
59. Inflammation and immune regulation by 12/15-lipoxygenases. H Kuhn VB O'Donnell, Prog Lipid Res 2006 45 4 334 356 10.1016/j.plipres.2006.02.003 16678271
60. Effect of size and dose on bone resorption activity of macrophages by in vitro clinically relevant ultra high molecular weight polyethylene particles. TR Green J Fisher JB Matthews MH Stone E Ingham, J Biomed Mater Res 2000 53 5 490 497 10.1002/1097-4636(200009)53:5<490::AID-JBM73.0.CO;2-7 10984696 (Pubitemid 30745180